AbbVie and Eisai Announce HUMIRA® Pre-filled Syringe 40 mg / 0.8 mL, a Fully Human Monoclonal Anti-TNF-a Antibody Formulation, Has Received Approval for the Treatment of Moderate to Severe Ulcerative Colitis (UC) in Japan (Eisai Co Ltd)

(Source: Eisai Co Ltd) HUMIRA Becomes the First and Only Self-Injectable Biologic Therapy for the Treatment of Moderate to Severe UC AbbVie GK Eisai Co., Ltd. AbbVie GK (Headquarters: Tokyo, President: Gary M. Winer, "AbbVie") and Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") today announced that they have received indication approval for the treatment of ulcerative colitis (UC) for HUMIRA® Pre-filled Syringe 40 mg / 0.8 mL (adalimumab; recombinant, "HUMIRA"), a fully human anti-TNF-α monoclonal antibody formulation. UC is a refractory disease that causes inflammation in the colon and rectum. The symptoms of UC, which may include...